Yahoo Finance

DALLAS, TX / ACCESSWIRE / November 23, 2020 / According to a new market report published by Lucintel, the future of the cancer biomarker market looks promising with opportunities in the diagnostics, research, prognostics, and risk assessment applications. The cancer biomarker market is expected to grow with a CAGR of 12% from 2019 to 2024. The major growth drivers for this market are growing demand of early diagnosis with accurate and consistent results, growing incidence of cancer, increasing use of cancer biomarker in drug discovery and development, and rising research on cancer biomarker.

To download report brochure, please go to https://www.lucintel.com/cancer-biomarker-market.aspx and click "report brochure" tab from the menu.

In this market, omics, imaging, immunoassays, cytogenetics, and bioinformatics are the major profiling technologies used to produce biomarkers which enhance cancer detection and facilitate high-speed noninvasive diagnosis. Omics technology is expected to witness the highest growth as it enables faster acquisition of genomic, proteomic, and metabolomic data.

Breast cancer, lung cancer, colorectal cancer, prostate cancer, non-hodgkin's lymphoma, melanoma, leukemia, thyroid cancer, bladder cancer, and kidney cancer are the major cancer types of the cancer biomarker market. Breast cancer is the largest application due to the high prevalence of breast cancer, increased awareness about breast cancer diagnosis, and increasing research focus on breast cancer.

North America is the largest region over the forecast period due to high incidence rate of cancer, growth in awareness on cancer.

Thermo Fisher Scientific, Roche Diagnostics, Qiagen N.V., Illumina, Agilent Technologies, Biomérieux, Merck & Co., Abbott Laboratories, Becton Dickinson, and Quest Diagnostics are among the major manufacturers of the cancer biomarker market.

Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the cancer biomarker market by biomolecules type, cancer type, profiling technology, method, application, and region. Lucintel has prepared a comprehensive research report titled "Cancer Biomarker Market 2019-2024: Trends, Forecast, and Opportunity Analysis". The Lucintel report serves as a catalyst for growth strategy as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes a forecast for the cancer biomarker market by biomolecules type, cancer type, profiling technology, method, application, and region as follows: